{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:03:34Z","timestamp":1761102214628},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T00:00:00Z","timestamp":1464566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Fundaci\u00f3n para el Estudio de la Hematolog\u00eda y Hemoterapia en Arag\u00f3n (FEEHA)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Non\u2010Hodgkin lymphoma patients have a 25% increased risk of secondary primary neoplasms (<jats:styled-content style=\"fixed-case\">SPNs<\/jats:styled-content>). Regarding the controversy about the increased risk of <jats:styled-content style=\"fixed-case\">SPN<\/jats:styled-content> in patients exposed to radioimmunotherapy (<jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content>), we have analyzed this issue in a cohort of follicular lymphoma (<jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content>) patients treated with\/without <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>A retrospective study including all consecutive <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> patients diagnosed since 2001 was performed. Demographic, clinical data including the incidence of any kind of neoplasm (excluding basocellular skin carcinoma) were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 242 patients were registered, male\/female: 103\/139, mean age: 59.9 yr (15\u201386), stage <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> (57.8%), and <jats:styled-content style=\"fixed-case\">Follicular Lymphoma Prognostic Index (FLIPI)<\/jats:styled-content> low\u2010risk (62.15%) predominance. Ninety\u2010six patients (39.7%) were treated with 90Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>. The median follow\u2010up for patients treated or not with 90Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> was 61 (8\u2013273) and 38 (1\u2013171) months. With respect to <jats:styled-content style=\"fixed-case\">SPN<\/jats:styled-content> incidence, 38 (15.6%) patients have at least two cancers, in 17 (44.7%), <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> was the <jats:styled-content style=\"fixed-case\">SPN<\/jats:styled-content>; for the rest (226), the global incidence of <jats:styled-content style=\"fixed-case\">SPN<\/jats:styled-content>s was 9.3% (21), but there were no differences related to the exposition or not to 90Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> (<jats:italic>P<\/jats:italic> = 0.26). In seven patients, more than two (2\u20136) different therapies were registered; four were exposed to fludarabine\u2010based therapy, three to radiotherapy and two to autologous stem\u2010cell transplantation, and in the <jats:styled-content style=\"fixed-case\">RIT<\/jats:styled-content> cohort, two patients developed myelodysplastic syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This is one of the largest single institution reports assessing the risk of <jats:styled-content style=\"fixed-case\">SPN<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">FL<\/jats:styled-content> patients treated (96) or not (146) with 90Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content>. It seems that 90Y\u2010<jats:styled-content style=\"fixed-case\">IT<\/jats:styled-content> does not increase significantly the risk of <jats:styled-content style=\"fixed-case\">SPN<\/jats:styled-content> but avoiding its use after fludarabine and other intense cytotoxic schemes is recommended.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12775","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T11:28:20Z","timestamp":1462793300000},"page":"576-582","source":"Crossref","is-referenced-by-count":8,"title":["Long\u2010term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90\u2010yttrium\u2010ibritumomab\u2010tiuxetan"],"prefix":"10.1111","volume":"97","author":[{"given":"Marcio Miguel","family":"Andrade\u2010Campos","sequence":"first","affiliation":[{"name":"Translational Research Unit Aragon Health Research Institute (IIS\u2010A) Zaragoza Spain"},{"name":"CIBER de Enfermedades Raras, CIBERER Instituto Aragon\u00e9s de Ciencias de la Salud (I+CS) Zaragoza Spain"},{"name":"Department of Hematology Miguel Servet University Hospital Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Li\u00e9vano","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Miguel Servet University Hospital Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Espinosa\u2010Lara","sequence":"additional","affiliation":[{"name":"Department of Hematology Miguel Servet University Hospital Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Soro\u2010Alcubierre","sequence":"additional","affiliation":[{"name":"Department of Hematology Miguel Servet University Hospital Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Grasa\u2010Ulrich","sequence":"additional","affiliation":[{"name":"Department of Hematology Miguel Servet University Hospital Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"L\u00f3pez\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Hematology Royo Villanova Hospital Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Baringo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Miguel Servet University Hospital Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[{"name":"Translational Research Unit Aragon Health Research Institute (IIS\u2010A) Zaragoza Spain"},{"name":"CIBER de Enfermedades Raras, CIBERER Instituto Aragon\u00e9s de Ciencias de la Salud (I+CS) Zaragoza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24086"},{"key":"e_1_2_9_3_1","volume-title":"Cancer Facts and Figures 2012","author":"American Cancer Society","year":"2012"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv376"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.05.009"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0092-5"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.09.012"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2145-6"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.18632\/oncotarget.6531","article-title":"90 Y\u2010ibritumomab tiuxetan: a nearly forgotten opportunity","volume":"7","author":"Mondello P","year":"2016","journal-title":"Oncotarget"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1007505"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1016929"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-1979-1"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1629-4"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01720510"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92007-3"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.02.025"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.953144"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12384"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-015-0012-3"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1636-5"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.088377"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.790544"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12775","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:09:12Z","timestamp":1696291752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,30]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/ejh.12775"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12775","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,30]]}}}